VEGFA and cancer: In a small study involving 40 patients who received VEGF inhibitors, 8% of the patients developed clinically asymptomatic cancer therapeutic-related cardiac dysfunction, and 30% developed clinically significant decreases in global longitudinal strain, which is a marker for early subclinical myocardial dysfunction [158].